The contract manufacturing market for biologics is growing at an unprecedented rate due to increasing biologics pipeline, manufacturing complexity, and companies shifting their focus toward core activities. Many pharmaceutical & biotechnology companies outsource varied services, such as early-stage drug development and commercial-scale manufacturing. Outsourcing is required to expedite research & development, speed up market entry, give access to novel technologies, provide regulatory expertise, and reduce risks at a competitive cost. Complexities in biologics development & production and increasingly stringent quality standards have driven drug manufacturers to prefer contract manufacturer services. The demand for contract manufacturing of biologics increased due to difficulties faced in producing large-scale biologics in-house. The production will increase after the approval of novel technologies, such as manufacturing CAR-T therapy. With more biological products and biosimilars entering the market, the competition is rising within the biopharmaceutical sector. Biologics manufacturers strive to reduce manufacturing costs, deliver high-quality drugs, improve process efficiency, and accelerate market entry. CMOs can adopt as per requirements and help in the innovation process and improve operational efficiency. As the pharmaceutical industry is shifting from large-scale production to niche and targeted therapies (personalized medicine), the demand for flexible operational capabilities, production scales, and multiple-product operations are offering significant advantages to contract manufacturing organizations (CMOs). Moreover, many companies are opting for CMOs services to speed up the development process and lower production costs, leading to the biopharmaceutical contract manufacturing market growth.
Europe Biopharmaceutical Contract Manufacturing Market Segmentation
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 4,610.37 Million |
| Market Size by 2028 | US$ 8,026.13 Million |
| CAGR (2021 - 2028) | 8.2% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product
|
|
Regions and Countries Covered
|
|
| Europe | UK, Germany, France, Russia, Italy, Rest of Europe |
| Market leaders and key company profiles |
|
The Europe Biopharmaceutical Contract Manufacturing Market is valued at US$ 4,610.37 Million in 2021, it is projected to reach US$ 8,026.13 Million by 2028.
As per our report Europe Biopharmaceutical Contract Manufacturing Market, the market size is valued at US$ 4,610.37 Million in 2021, projecting it to reach US$ 8,026.13 Million by 2028. This translates to a CAGR of approximately 8.2% during the forecast period.
The Europe Biopharmaceutical Contract Manufacturing Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Biopharmaceutical Contract Manufacturing Market report:
The Europe Biopharmaceutical Contract Manufacturing Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Biopharmaceutical Contract Manufacturing Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Biopharmaceutical Contract Manufacturing Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For Europe Biopharmaceutical Contract Manufacturing Market
